

Title (en)
USE OF EPIGALLOCATECHIN GALLATE AS AN ANTIVIRAL AGENT AGAINST INFECTIONS BY THE HEPATITIS C VIRUS

Title (de)
VERWENDUNG VON EPIGALLOCATECHINGALLAT ALS VIRUZID GEGEN HEPATITIS-C-VIRUS-INFEKTIONEN

Title (fr)
UTILISATION DE L'EPIGALLOCATECHINE GALLATE COMME AGENT ANTIVIRAL CONTRE LES INFECTIONS PAR LE VIRUS DE L'HÉPATITE C

Publication
EP 2691091 A1 20140205 (FR)

Application
EP 12711160 A 20120328

Priority
• FR 1152536 A 20110328
• EP 2012055533 W 20120328

Abstract (en)
[origin: WO2012130893A1] The present invention relates to a flavonoid compound of formula I, where R3, R5 and/or R7 is a group of formula II, or R1 and R2 are both OH groups, or to one of the pharmaceutically acceptable salts or esters thereof, for use as an antiviral agent in the treatment and/or prevention of a hepatitis C virus (HCV) infection. The invention also relates to an ex vivo method for reducing the infectivity of HCV or for inactivating HCV, including a step of contacting said hepatitis C virus with a compound of formula (I).

IPC 8 full level
A61K 31/353 (2006.01); **A61P 31/14** (2006.01)

CPC (source: EP US)
A61K 31/352 (2013.01 - EP US); **A61K 31/353** (2013.01 - EP US); **A61K 45/06** (2013.01 - US); **A61P 31/14** (2017.12 - EP); **C12N 2770/24211** (2013.01 - EP US)

Citation (search report)
See references of WO 2012130893A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)
WO 2012130893 A1 20121004; BR 112013024904 A2 20190924; CN 103826626 A 20140528; EP 2691091 A1 20140205; FR 2973249 A1 20121005; FR 2973249 B1 20140207; JP 2014510740 A 20140501; US 2014088184 A1 20140327

DOCDB simple family (application)
EP 2012055533 W 20120328; BR 112013024904 A 20120328; CN 201280026189 A 20120328; EP 12711160 A 20120328; FR 1152536 A 20110328; JP 2014501600 A 20120328; US 201214008031 A 20120328